Incidence and inhospital outcomes of coronavirus disease 2019-associated pulmonary aspergillosis in the United States.

IF 2.1 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Annals of Thoracic Medicine Pub Date : 2024-01-01 Epub Date: 2024-01-25 DOI:10.4103/atm.atm_190_23
Aditya Sharma, Aditi Sharma, Ayman O Soubani
{"title":"Incidence and inhospital outcomes of coronavirus disease 2019-associated pulmonary aspergillosis in the United States.","authors":"Aditya Sharma, Aditi Sharma, Ayman O Soubani","doi":"10.4103/atm.atm_190_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to estimate the predictors, associations, and outcomes of COVID-19-associated pulmonary disease (CAPA) in the United States.</p><p><strong>Study design and methods: </strong>This retrospective cohort study was performed by using the National Inpatient Sample Database 2020 to identify coronavirus disease 2019 (COVID-19) and CAPA hospitalizations. Baseline variables and outcomes were compared between COVID-19 hospitalizations without aspergillosis and those with aspergillosis. These variables were then used to perform an adjusted analysis for obtaining predictors and factors associated with CAPA and its inhospital mortality.</p><p><strong>Results: </strong>Of the 1,020,880 hospitalizations identified with the principal diagnosis of COVID-19, CAPA was identified in 1510 (0.1%) hospitalizations. The CAPA cohort consisted of a higher proportion of males (58%) as well as racial and ethnic minorities (Hispanics, Blacks, and others [including Asian or Pacific islanders, native Americans]). Inhospital mortality was significantly higher (47.35% vs. 10.87%, <i>P</i> < 0.001), the average length of stay was longer (27.61 vs. 7.29 days, <i>P</i> < 0.001), and the mean cost per hospitalization was higher ($121,560 vs. $18,423, <i>P</i> < 0.001) in the CAPA group compared to COVID-19 without aspergillosis. History of solid organ transplant, chronic obstructive pulmonary disease, and venous thromboembolism were associated with higher odds of CAPA among other factors. The use of invasive mechanical ventilation (adjusted odds ratio [aOR] 6.24, <i>P</i> < 0.001), acute kidney injury (aOR 2.02, <i>P</i> = 0.028), and septic shock (aOR 2.07, <i>P</i> = 0.018) were associated with higher inhospital mortality in the CAPA cohort.</p><p><strong>Conclusion: </strong>While CAPA is an infrequent complication during hospitalizations for COVID-19, it significantly increases all-cause mortality, prolongs hospital stays, and leads to higher hospital expenses compared to COVID-19 cases without aspergillosis.</p>","PeriodicalId":50760,"journal":{"name":"Annals of Thoracic Medicine","volume":"19 1","pages":"87-95"},"PeriodicalIF":2.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911242/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/atm.atm_190_23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The aim of this study was to estimate the predictors, associations, and outcomes of COVID-19-associated pulmonary disease (CAPA) in the United States.

Study design and methods: This retrospective cohort study was performed by using the National Inpatient Sample Database 2020 to identify coronavirus disease 2019 (COVID-19) and CAPA hospitalizations. Baseline variables and outcomes were compared between COVID-19 hospitalizations without aspergillosis and those with aspergillosis. These variables were then used to perform an adjusted analysis for obtaining predictors and factors associated with CAPA and its inhospital mortality.

Results: Of the 1,020,880 hospitalizations identified with the principal diagnosis of COVID-19, CAPA was identified in 1510 (0.1%) hospitalizations. The CAPA cohort consisted of a higher proportion of males (58%) as well as racial and ethnic minorities (Hispanics, Blacks, and others [including Asian or Pacific islanders, native Americans]). Inhospital mortality was significantly higher (47.35% vs. 10.87%, P < 0.001), the average length of stay was longer (27.61 vs. 7.29 days, P < 0.001), and the mean cost per hospitalization was higher ($121,560 vs. $18,423, P < 0.001) in the CAPA group compared to COVID-19 without aspergillosis. History of solid organ transplant, chronic obstructive pulmonary disease, and venous thromboembolism were associated with higher odds of CAPA among other factors. The use of invasive mechanical ventilation (adjusted odds ratio [aOR] 6.24, P < 0.001), acute kidney injury (aOR 2.02, P = 0.028), and septic shock (aOR 2.07, P = 0.018) were associated with higher inhospital mortality in the CAPA cohort.

Conclusion: While CAPA is an infrequent complication during hospitalizations for COVID-19, it significantly increases all-cause mortality, prolongs hospital stays, and leads to higher hospital expenses compared to COVID-19 cases without aspergillosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
美国2019年冠状病毒病相关肺曲霉病的发病率和住院治疗结果。
研究目的本研究旨在估算美国COVID-19相关肺病(CAPA)的预测因素、关联性和结果:这项回顾性队列研究利用 2020 年全国住院病人抽样数据库(National Inpatient Sample Database 2020)来识别 2019 年冠状病毒病(COVID-19)和 CAPA 住院病例。比较了无曲霉菌病和有曲霉菌病的 COVID-19 住院患者的基线变量和结果。然后利用这些变量进行调整分析,以获得与CAPA及其住院死亡率相关的预测因子和因素:在主要诊断为COVID-19的1,020,880例住院病例中,有1510例(0.1%)住院病例被确诊为CAPA。CAPA队列中男性比例较高(58%),少数种族和族裔(西班牙裔、黑人和其他[包括亚洲或太平洋岛民、美国本地人])也较多。与无曲霉菌病的 COVID-19 相比,CAPA 组的住院死亡率明显更高(47.35% 对 10.87%,P<0.001),平均住院时间更长(27.61 天对 7.29 天,P<0.001),每次住院的平均费用更高(121560 美元对 18423 美元,P<0.001)。除其他因素外,实体器官移植史、慢性阻塞性肺病和静脉血栓栓塞与较高的CAPA几率相关。在CAPA队列中,使用有创机械通气(调整赔率比[aOR]6.24,P<0.001)、急性肾损伤(aOR 2.02,P=0.028)和脓毒性休克(aOR 2.07,P=0.018)与较高的院内死亡率相关:结论:虽然CAPA在COVID-19住院期间是一种不常见的并发症,但与未患曲霉菌病的COVID-19病例相比,CAPA会显著增加全因死亡率、延长住院时间并导致更高的住院费用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of Thoracic Medicine
Annals of Thoracic Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-RESPIRATORY SYSTEM
CiteScore
4.10
自引率
4.30%
发文量
19
审稿时长
>12 weeks
期刊介绍: The journal will cover studies related to multidisciplinary specialties of chest medicine, such as adult and pediatrics pulmonology, thoracic surgery, critical care medicine, respiratory care, transplantation, sleep medicine, related basic medical sciences, and more. The journal also features basic science, special reports, case reports, board review , and more. Editorials and communications to the editor that explore controversial issues and encourage further discussion by physicians dealing with chest medicine.
期刊最新文献
Effect of surgery on survival of patients with small-cell lung cancer undiagnosed before resection. Investigating the dynamic relationship of sleep-disordered breathing, orthodontic treatment needs, and dental esthetics in the general population. Is chest tube omission safe for patients with primary spontaneous pneumothorax scheduled for video-assisted thoracoscopic surgery? Sleep disorders among elderly in Saudi Arabia: A cross-sectional study. To assess the differences between thymoma patients with/without myasthenia all of their characteristics must be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1